David B Agus

List of Publications by Year
in descending order

22 papers	715 citations	687363 13 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	1401 citing authors

#	Article	IF	Citations
1	A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports, 2013, 3, 1449.	3.3	146
2	Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nature Communications, 2020, 11, 5727.	12.8	126
3	Deep learned tissue â€œfingerprintsâ€•classify breast cancers by ER/PR/Her2 status from H&E images. Scientific Reports, 2020, 10, 7275.	3.3	60
4	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics, 2015, 14s4, CIN.S19338.	1.9	59
5	A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Scientific Reports, 2016, 6, 29752.	3.3	50
6	Design and rationale for the I nfluenza vaccination A fter M yocardial I nfarction (IAMI) trial. A registry-based randomized clinical trial. American Heart Journal, 2017, 189, 94-102.	2.7	39
7	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 61-68.	3.9	34
8	Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. Npj Breast Cancer, 2018, 4, 32.	5.2	27
9	Quantifying differences in cell line population dynamics using CellPD. BMC Systems Biology, 2016, 10, 92.	3.0	21
10	Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Research Notes, 2019, 12, 275.	1.4	19
11	JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2017, 16, 1645-1657.	4.1	18
12	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. Journal of Clinical Oncology, 2014, 32, 7-7.	1.6	17
13	Single cell dynamic phenotyping. Scientific Reports, 2016, 6, 34785.	3.3	16
14	Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Medicine, 2016, 8, 54.	8.2	12
15	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clinical Genitourinary Cancer, 2018, 16, e11-e21.	1.9	9
16	Cancer Moonshot 2.0. Lancet Oncology, The, 2021, 22, 164-165.	10.7	9
17	Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Scientific Reports, 2016, 6, 22435.	3.3	7
18	High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth. GigaScience, 2021, 10, .	6.4	7

#	Article	IF	Citations
19	A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.. Journal of Clinical Oncology, 2013, 31, 59-59.	1.6	7
20	The sciences converge to fight cancer. Nature Physics, 2012, 8, 773-774.	16.7	6
21	Stochasticity and determinism in cancer creation and progression. Convergent Science Physical Oncology, 2015, 1, 026003.	2.6	3
22	Paradoxical androgen receptor regulation by small molecule enantiomers. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2